Corbus Pharmaceuticals Holdings, Inc. Capital Expenditures Incurred but Not yet Paid
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Capital Expenditures Incurred but Not yet Paid of $376.66 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2021-03-15
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-12-31 was -$853.25K.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-09-30 was $970.18K, a 1585.87% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-06-30 was $190.27K.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-03-31 was $69.46K, a 86.32% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2019 was $376.66K, a 32148.63% increase from fiscal 2018.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2018 was $1.17K, a 99.80% decline from fiscal 2017.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2017 was $579.73K, a 1599.75% increase from fiscal 2016.
- Corbus Pharmaceuticals Holdings, Inc. capital expenditures incurred but not yet paid for fiscal 2016 was $34.11K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$853.25K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $116.93K derived: sum of 2 quarters · filed 2021-03-15 | $307.20K derived: sum of 3 quarters · filed 2021-03-15 | $376.66K 10-K · filed 2021-03-15 |
| 2019-09-30 | $970.18K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-09 | $1.16M derived: sum of 2 quarters · filed 2020-11-09 | $1.23M 10-Q · filed 2020-11-09 | $1.14M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $190.27K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | $259.73K 10-Q/A · filed 2020-08-31 | $168.20K derived: sum of 3 quarters · filed 2020-08-31 | $225.75K derived: sum of 4 quarters · filed 2020-08-31 |
| 2019-03-31 | $69.46K 10-Q · filed 2020-05-11 | -$22.07K derived: sum of 2 quarters · filed 2020-05-11 | $35.48K derived: sum of 3 quarters · filed 2020-05-11 | -$437.17K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | -$91.53K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$33.98K derived: sum of 2 quarters · filed 2020-03-16 | -$506.63K derived: sum of 3 quarters · filed 2020-03-16 | $1.17K 10-K · filed 2020-03-16 |
| 2018-09-30 | $57.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$415.10K derived: sum of 2 quarters · filed 2019-11-07 | $92.70K 10-Q · filed 2019-11-07 | |
| 2018-06-30 | -$472.65K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $35.15K 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $507.80K 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $579.73K 10-K · filed 2019-03-12 | |||
| 2016-12-31 | $20.11K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $28.63K derived: sum of 2 quarters · filed 2018-03-12 | -$78.61K derived: sum of 3 quarters · filed 2018-03-12 | $34.11K 10-K · filed 2018-03-12 |
| 2016-09-30 | $8.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$98.72K derived: sum of 2 quarters · filed 2017-11-08 | $14.00K 10-Q · filed 2017-11-08 | |
| 2016-06-30 | -$107.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.48K 10-Q · filed 2017-08-09 | ||
| 2016-03-31 | $112.72K 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |